CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
Cancer Trials Ireland
Mayo Clinic
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Fred Hutchinson Cancer Center
Washington University School of Medicine
University of California, San Francisco
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
University of California, San Francisco
Hackensack Meridian Health
Juno Therapeutics, a Subsidiary of Celgene
Dana-Farber Cancer Institute
Fate Therapeutics
Case Comprehensive Cancer Center
Caribou Biosciences, Inc.
Case Comprehensive Cancer Center
University of Pennsylvania
Cartesian Therapeutics
Cartesian Therapeutics
Jonsson Comprehensive Cancer Center
Sanofi
Gilead Sciences
Fred Hutchinson Cancer Center
Gilead Sciences
Precision BioSciences, Inc.
Fate Therapeutics
Fred Hutchinson Cancer Center
Celyad Oncology SA
Celgene
Allogene Therapeutics
Melbourne Health
University of Pennsylvania
Shanghai Pudong Hospital
M.D. Anderson Cancer Center
Second Affiliated Hospital, School of Medicine, Zhejiang University
GlaxoSmithKline
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
First Affiliated Hospital of Zhejiang University
Case Comprehensive Cancer Center
Massachusetts General Hospital
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins